Plasma homocysteine levels in pergolide-treated Parkinson disease patients

Ozkan S., Colak O., Kutlu C., Ertan M., Alatas O.

CLINICAL NEUROPHARMACOLOGY, vol.27, no.4, pp.163-165, 2004 (SCI-Expanded) identifier

  • Publication Type: Article / Review
  • Volume: 27 Issue: 4
  • Publication Date: 2004
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.163-165
  • Eskisehir Osmangazi University Affiliated: Yes


Hyperhomocysteinemia is as a risk factor for increased vascular disease in L-dopa-treated Parkinson disease (PD) patients. This effect Of L-dopa is associated with the metabolism Of L-dopa by methylation. This study aimed to assess the effect of pergolide on plasma homocysteine levels. Plasma homocysteine levels were compared between PD patients treated with pergolide as monotherapy, with L-dopa as monotherapy, or with an L-dopa and pergolide combination and compared with controls. Plasma homocysteine levels were significantly higher in the L-dopa monotherapy group, and there were no significant differences for the pergolide treatment groups. Pergolide can be beneficial for increased plasma homocysteine levels.